Zacks Investment Research Lowers Regulus Therapeutics (NASDAQ:RGLS) to Hold

Zacks Investment Research cut shares of Regulus Therapeutics (NASDAQ:RGLS) from a buy rating to a hold rating in a report released on Tuesday morning, reports.

According to Zacks, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. “

A number of other analysts also recently weighed in on the stock. ValuEngine downgraded shares of Regulus Therapeutics from a hold rating to a sell rating in a research report on Wednesday, January 8th. Wedbush reaffirmed a hold rating and issued a $1.00 target price on shares of Regulus Therapeutics in a research report on Monday, December 16th. One analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company’s stock. The company has an average rating of Hold and a consensus price target of $1.31.

Regulus Therapeutics stock traded down $0.03 during mid-day trading on Tuesday, reaching $1.21. 217,388 shares of the company traded hands, compared to its average volume of 544,469. The firm’s 50 day moving average price is $0.88 and its 200 day moving average price is $0.80. The firm has a market capitalization of $25.53 million, a price-to-earnings ratio of -0.22 and a beta of 1.57. Regulus Therapeutics has a 52-week low of $0.50 and a 52-week high of $1.74.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.26). The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.02 million. As a group, analysts anticipate that Regulus Therapeutics will post -1.11 EPS for the current fiscal year.

An institutional investor recently bought a new position in Regulus Therapeutics stock. Samsara BioCapital LLC bought a new position in Regulus Therapeutics Inc (NASDAQ:RGLS) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor bought 904,407 shares of the biopharmaceutical company’s stock, valued at approximately $1,131,000. Regulus Therapeutics accounts for about 0.7% of Samsara BioCapital LLC’s holdings, making the stock its 17th biggest holding. Samsara BioCapital LLC owned approximately 4.36% of Regulus Therapeutics as of its most recent SEC filing. Institutional investors own 36.84% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

Featured Story: Percentage Gainers

Get a free copy of the Zacks research report on Regulus Therapeutics (RGLS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with's FREE daily email newsletter.